Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction

被引:0
作者
Sun, J [1 ]
He, ZG [1 ]
Cheng, G [1 ]
Wang, SJ [1 ]
Hao, XH [1 ]
Zou, MJ [1 ]
机构
[1] Shenyang Pharmaceut Univ, Sch Pharm, Dept Biopharmaceut, Shenyang 110016, Peoples R China
来源
MEDICAL SCIENCE MONITOR | 2004年 / 10卷 / 01期
关键词
P-glycoprotein; drug disposition; drug interaction; polymorphism; dietary components; pharmaceutical excipients;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
This article reviews recent advances in our understanding of the structure, drug interaction mechanism, and substrate molecular requirements of P-glycoprotein (P-gp) and its emerging crucial role in drug disposition and the modulation of drug interaction. In view of its wide localization in normal tissues, the broad variety of structurally and functionally unrelated substrates of P-gp, and its ATP-dependent outward-oriented transport, P-gp actively participates in intestinal secretion, blood-tissue barriers, and biliary and renal excretions for many exogenous substrates, and also performs a protective role to prevent entry of xenobiotics. Moreover, the importance of P-gp-mediated drug interactions in clinical practice can hardly be underestimated, since it may result in severe side effects, such as digitalis drug interaction. Polymorphism or single nucleotide polymorphism (SNP) associated with P-gp may exert a significant effect on the pharmacokinetic behavior of its substrates, a fact which has major clinical implications and suggests careful dose adjustment for individual treatment. Moreover, dietary components and pharmaceutical excipients may modulate P-gp activity, and as a result affect in vivo drug disposition and therapeutic efficacy; examples include grapefruit juice, Pluronic P85, PEG 300, etc.. In summary, it should be emphasized that P-gp is an integral component in the process of drug discovery, development strategy, and clinical therapy.
引用
收藏
页码:RA5 / RA14
页数:10
相关论文
共 86 条
[1]  
AKIYAMA SI, 1988, MOL PHARMACOL, V33, P144
[2]   Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].
Ambudkar, SV ;
Dey, S ;
Hrycyna, CA ;
Ramachandra, M ;
Pastan, I ;
Gottesman, MM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :361-398
[3]   MDR1 pharmacogenetics:: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity [J].
Ameyaw, MM ;
Regateiro, F ;
Li, T ;
Liu, XH ;
Tariq, M ;
Mobarek, A ;
Thornton, N ;
Folayan, GO ;
Githang'a, J ;
Indalo, A ;
Ofori-Adjei, D ;
Price-Evans, DA ;
McLeod, HL .
PHARMACOGENETICS, 2001, 11 (03) :217-221
[4]  
Arimoa H, 2001, J PHARMACOL EXP THER, V297, P547
[5]   DISCRETE MUTATIONS INTRODUCED IN THE PREDICTED NUCLEOTIDE-BINDING SITES OF THE MDR1 GENE ABOLISH ITS ABILITY TO CONFER MULTIDRUG RESISTANCE [J].
AZZARIA, M ;
SCHURR, E ;
GROS, P .
MOLECULAR AND CELLULAR BIOLOGY, 1989, 9 (12) :5289-5297
[6]   Multidrug resistance-associated protein: A protein distinct from p-glycoprotein involved in cytotoxic drug expulsion [J].
Barrand, MA ;
Bagrij, T ;
Neo, SY .
GENERAL PHARMACOLOGY, 1997, 28 (05) :639-645
[7]   Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers [J].
Batrakova, EV ;
Li, S ;
Miller, DW ;
Kabanov, AV .
PHARMACEUTICAL RESEARCH, 1999, 16 (09) :1366-1372
[8]  
Beck W T, 1991, Cancer Treat Res, V57, P151
[9]   Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population [J].
Bernal, ML ;
Sinues, B ;
Fanlo, A ;
Mayayo, E .
THERAPEUTIC DRUG MONITORING, 2003, 25 (01) :107-111
[10]  
BOSCH I, 1996, BIOCHIM BIOPHYS ACTA, V1288, P37